NBIX demonstrated strong financial performance with meaningfully higher profitability and operating cash flow generation, while expanding its balance sheet substantially.
The company's net income grew substantially alongside a meaningful increase in operating cash flow, indicating robust operational execution and improved profitability. The significant expansion of both current assets and receivables suggests growing commercial success, likely driven by increased sales of their neurological treatments.
NBIX showed strong financial momentum with net income and operating cash flow both growing meaningfully year-over-year, while R&D expenses increased modestly as the company continues investing in its pipeline. The balance sheet expanded substantially with current assets and receivables both growing over 40%, indicating robust commercial activity, though this was matched by proportional increases in current liabilities. The company maintained a strong equity position with stockholders' equity growing to $3.3B, while reducing share buybacks and interest expense.
Current liabilities surged 46.4% — significant near-term obligations; verify ability to meet short-term debt.
Current assets grew 46.3% — improving short-term liquidity or inventory/receivables build.
Buyback activity reduced 44.1% — capital being redeployed elsewhere or cash conservation underway.
Receivables surged 43.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Net income grew 40.2% — bottom-line growth signals improving overall business health.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
R&D investment increased 31.8% — signals commitment to future product development, though near-term margin impact.
Operating cash flow surged 31.5% — exceptional cash generation, highest quality earnings signal.
Equity base grew 25.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 24.5% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →